Treatment: Sweet liking phenotype, alcohol craving and response to naltrexone treatment in alcohol dependence

Alcohol and Alcoholism

Volumn 44, Issue 3, 2009, Pages 293-300

  Garbutt, James C ^a   Osborne, Michael ^a   Gallop, Robert ^b   Barkenbus, John ^a   Grace, Kathy ^a   Cody, Meghan ^a   Flannery, Barbara ^c   Kampov Polevoy, Alexey B ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b WEST CHESTER UNIVERSITY   (United States)

^c RTI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NALTREXONE;

ADULT; ALCOHOL WITHDRAWAL; ALCOHOLISM; ARTICLE; BRAIN FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG RESPONSE; FEMALE; HUMAN; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COUNSELING; PHENOTYPE; PRIORITY JOURNAL; SWEETNESS; TASTE PREFERENCE; ADDICTION; COMPARATIVE STUDY; DRUG EFFECT; GENETICS; MIDDLE AGED; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; TASTE; TREATMENT OUTCOME;

ADULT; ALCOHOLISM; BEHAVIOR, ADDICTIVE; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; PHENOTYPE; QUESTIONNAIRES; TASTE; TREATMENT OUTCOME;

EID: 65549145992     PISSN: 07350414     EISSN: 14643502     Source Type: Journal    
DOI: 10.1093/alcalc/agn122     Document Type: Article

References (58)

1. Allison PD. (1997) Survival analysis using the Sas system: A practical guide, SAS Publishing, Cary, North Carolina.
2. Anton RF, Oroszi G, O'Malley S et al. (2008) An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: Results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 65: 135-44.
3. Bencherif B, Wand GS, McCaul ME et al. (2004) Mu-opioid receptor binding measured by [11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence. Biol Psychiatry 55:255-62.
4. Bond C, LaForge KS, Tian M et al. (1998) Single-nucleotide polymorphism in the human mu-opioid receptor gene alters beta-endorphin binding and activity: Possible implications for opiate addiction. Proc Natl Acad Sci USA 95:9608-13.
5. Bouza C, Angeles M, Muñnoz A et al. (2004) Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. Addiction 99:811-28.
6. Calcagnetti DJ, Reid LD. (1983) Morphine and acceptability of putative reinforcers. Pharmacol Biochem Behav 18:567-9.
7. Cloninger CR. (1987) Neurogenetic adaptive mechanisms in alcoholism. Science 236:410-6.
8. Drewnowski A, Krahn DD, Demitrack MA et al. (1995) Naloxone, an opiate blocker, reduces the consumption of sweet high-fat foods in obese and lean female binge eaters. Am J Clin Nutr 61:1206-12.
9. Drobes DJ, Thomas SE. (1999) Assessing craving for alcohol. Alcohol Res Health 23:179-86.
10. Flannery BA, Poole SA, Gallop RJ et al. (2003) Alcohol craving predicts drinking during treatment: An analysis of three assessment instruments. J Stud Alcohol 64:120-6.
11. Flannery BA, Roberts AJ, Cooney N et al. (2001) The role of craving in alcohol use, dependence, and treatment. Alcohol Clin Exp Res 25:299-308.
12. Flannery BA, Volpicelli JR, Pettinati HM. (1999) Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res 23 1289-95.
13. Garbutt JC, Kranzler HR, O'Malley SS et al. Vivitrex Study Group. (2005) Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. JAMA 293 1617-25.
14. Gelernter J, Gueorguieva R, Kranzler HR et al. VA Cooperative Study #425 Study Group. (2007) Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: Results from the VA Cooperative Study. Alcohol Clin Exp Res 31:555-63.
15. Gianoulakis C, Béliveau D, Angelogianni P et al. (1989) Different pituitary beta-endorphin and adrenal cortisol response to ethanol in individuals with high and low risk for future development of alcoholism. Life Sci 45:1097-109.
16. Gianoulakis C, Krishnan B, Thavundayil J. (1996) Enhanced sensitivity of pituitary beta-endorphin to ethanol in subjects at high risk of alcoholism. Arch Gen Psychiatry 53:250-7.
17. Gianoulakis C. (2004) Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr Top Med Chem 4:39-50.
18. Greenfield SF, Trucco E, Lincoln M et al. (2007) The Women's Recovery Group Study: A stage I trial of women-focused group therapy for substance use disorder versus mixed-gender group drug counseling. Drug Alcohol Depend 90:39-47.
19. Heinz A, Reimold M, Wrase J et al. (2005) Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: A positron emission tomography study using carbon 11-labeled carfentanil. Arch Gen Psychiatry 62:57-64.
20. Jaffe AJ, Rounsaville B, Chang G et al. (1996) Naltrexone, relapse prevention, and supportive therapy with alcoholics: An analysis of patient treatment matching. J Consult Clin Psychol 64 1044-53.
21. Kampov-Polevoy AB, Garbutt JC, Janowsky D. (1997) Evidence of preference for a higher concentration sucrose solution in alcoholic men. American Journal of Psychiatry 154:269-270.
22. Kampov-Polevoy AB, Garbutt JC, Janowsky DS. (1999) Association between preference for sweets and excessive alcohol intake: A review of animal and human studies. Alcohol Alcohol. 34:386-95.
23. Kampov-Polevoy AB, Garbutt JC, Khalitov E. (2003b) Family history of alcoholism and response to sweets. Alcohol Clin Exp Res 27 1743-9.
24. Kampov-Polevoy AB, Ziedonis D, Steinberg ML et al. (2003a) Association between sweet preference and paternal history of alcoholism in psychiatric and substance abuse patients. Alcohol Clin Exp Res 27:1929-36.
25. Keskitalo K, Tuorila H, Spector TD et al. (2007) Same genetic components underlie different measures of sweet taste preference. Am J Clin Nutr 86:1663-9.
26. Kiefer F, Helwig H, Tarnaske T et al. (2005) Pharmacological relapse prevention of alcoholism: Clinical predictors of outcome. Eur Addict Res 11:83-91.
27. King AC, Volpicelli JR, Frazer A, O'Brien CP. (1997) Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology 129 15-22.
28. Kranzler HR, Sandstrom KA, Van Kirk J. (2001) Sweet taste preference as a risk factor for alcohol dependence. Am J Psychiatry 158 813-5.
29. Kranzler HR, Van Kirk J. (2001) Efficacy of naltrexone and acamprosate for alcoholism treatment: A meta-analysis. Alcohol Clin Exp Res 25:1335-41.
30. Leventhal L, Kirkham TC, Cole JL et al. (1995) Selective actions of central mu and kappa opioid antagonists upon sucrose intake in sham-fed rats. Brain Res 685:205-10.
31. Littell RC, Milliken GA, Stroup WW et al. (2006) SAS System for Mixed Models Second Edition. Cary, NC: SAS Institute Inc.
32. Looy H, Callaghan S, Weingarten HP. (1992) Hedonic response of sucrose likers and dislikers to other gustatory stimuli. Physiol Behav 52:219-25.
33. Mark TL, Kranzler HR, Song X. (2003) Understanding US addiction physicians' low rate of naltrexone prescription. Drug Alcohol Depend 71:219-28
34. Mennella JA, Pepino MY, Reed DR. (2005) Genetic and environmental determinants of bitter perception and sweet preferences. Pediatrics 115:e216-22.
35. Monterosso JR, Flannery BA, Pettinati HM et al. (2001) Predicting treatment response to naltrexone: The influence of craving and family history. Am J Addict 10:258-68.
36. National Institutes of Health. Project Match Series, Volume 2 (1994) Motivational Enhancement Therapy Manual. NIH Pub. No. 94-3723.
37. O'Malley SS, Jaffe AJ, Rode S et al. (1996) Experience of a 'slip' among alcoholics treated with naltrexone or placebo. Am J Psychiatry 153:281-3.
38. O'Malley SS, Krishnan-Sarin S, Farren C et al. (2000) Naltrexone-induced nausea in patients treated for alcohol dependence: clinical predictors and evidence for opioid-mediated effects. J Clin Psychopharmacol 20:69-76.
39. Oslin DW, Berrettini W, Kranzler HR et al. (2003) A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28:1546-52.
40. Pecina S, Berridge KC. (2005) Hedonic hot spot in nucleus accumbens shell: Where do mu-opioids cause increased hedonic impact of sweetness? J Neurosci 25:11777-86.
41. Pepino MY, Mennella JA. (2007) Effects of cigarette smoking and family history of alcoholism on sweet taste perception and food cravings in women. Alcohol Clin Exp Res 31:1891-9.
42. Rohsenow DJ, Miranda R Jr, McGeary JE et al. (2007) Family history and antisocial traits moderate naltrexone's effects on heavy drinking in alcoholics. Exp Clin Psychopharmacol 15:272-81.
43. Rothman KJ. (1990) No adjustments are needed for multiple comparisons. Epidemiology 1:43-6.
44. Rubio G, Ponce G, Rodriguez-Jimenez R et al. (2005) Clinical predictors of response to naltrexone in alcoholic patients: Who benefits most from treatment with naltrexone? Alcohol Alcohol 40 227-33.
45. Schwarz CJ. (1993) The mixed-model ANOVA: The truth, the computer packages, the books. Am Statistician 47:48-59.
46. Scinska A, Bogucka-Bonikowska A, Koros E et al. (2001) Taste responses in sons of male alcoholics. Alcohol Alcohol 36 79-84.
47. Sheehan D, Janavs J, Baker R et al. (1999) Mini International Neuropsychiatric Interview (M.I.N.I.). Tampa: University of South Florida.
48. Sobell LC, Sobell MB, Leo GL et al. (1988) Reliability of a timeline followback method: Assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. British Journal of Addictions 83:393-402.
49. Srisurapanont M, Jarusuraisin N. (2002) Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2: CD001867.
50. Streeton C, Whelan G. (2001) Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: A meta-analysis of randomized controlled trials. Alcohol Alcohol 36:544-52.
51. Sullivan JT, Sykora K, Schneiderman J et al. (1989) Assessment of alcohol withdrawal: The revised Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA-Ar). Br J Addict 84: 1353-7.
52. Thompson DA, Moskowitz HR, Campbell RG. (1976) Effects of body weight and food intake on pleasantness ratings for a sweet stimulus. J Appl Physiol 41:77-83.
53. Tidey JW, Monti PM, Rohsenow DJ et al. (2008) Moderators of naltrexone's effects on drinking, urge, and alcohol effects in nontreatment-seeking heavy drinkers in the natural environment. Alcohol Clin Exp Res 32:58-66.
54. Van Den Wildenberg E, Wiers RW, Dessers J et al. (2007) A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers. Alcohol Clin Exp Res 31:1-10.
55. Volpicelli JR, Alterman AI, Hayashida M et al. (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49 876-80.
56. Volpicelli JR, Clay KL, Watson NT et al. (1995) Naltrexone in the treatment of alcoholism: Predicting response to naltrexone. J Clin Psychiatry 56 (Suppl 7):39-44.
57. Wand GS, McCaul M, Yang X et al. (2002) The μ-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 26:106-14.
58. Wronski M, Skrok-Wolska D, Samochowiec J et al. (2007) Perceived intensity and pleasantness of sucrose taste in male alcoholics. Alcohol Alcohol 42:75-9.